Anti-CD70 CAR T cell therapy (Allogene Therapeutics)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAnti-CD70 CAR T cell therapy (Allogene Therapeutics)

Drug Alias NameCD70 targeted CAR-T cell therapy - Allogene Therapeutics

ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacementsAnti-CD70

TargetsCD70 antigen

Therapy Area/IndicationsCarcinoma, Renal CellLymphoma, Non-Hodgkin

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesAllogene Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesAllogene Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsCarcinoma, Renal CellLymphoma, Non-Hodgkin

Inactive IndicationsN/A

Other Information

ATC CodeN/A